Baird lowered the firm’s price target on Calidi to $2.50 from $20 and keeps a Neutral rating on the shares. The firm updated its model for 2Q24 earnings where they attribute $20M in value to the company’s platform and property and then divide by 8M shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDI:
- Calidi Biotherapeutics Unveils Redtail Biopharma Subsidiary
- Calidi Biotherapeutics Board Reshuffles as Advisor Departs
- Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results
- Calidi Biotherapeutics Secures Investment, Expands Advisory Board
- Calidi announces launch of Nova Cell, $3M investment